keyword
https://read.qxmd.com/read/38648029/loss-of-p16-immunoexpression-and-deletions-of-cdkn2a-in-the-progression-of-extramammary-paget-disease-an-immunohistochemical-and-genetic-study-of-24-invasive-metastatic-cases
#1
JOURNAL ARTICLE
Tsubasa Hiraki, Takuma Oishi, Shusuke Yoshikawa, Keiichiro Honma, Shuichi Ohe, Taiki Isei, Yoji Kukita, Toshihiro Takai, Keiji Shimada, Yusuke Takei, Keisuke Goto
Information regarding the genetic alterations in extramammary Paget disease (EMPD) is scarce. This study investigated the significance of CDKN2A and MTAP alterations in EMPD progression using immunohistochemistry and panel DNA sequencing. In total, 24 invasive/metastatic EMPD cases were included in this study. The immunoexpression of p16 and MTAP in the primary in situ, primary invasive, and metastatic tumor components was evaluated. Panel DNA sequencing was performed for metastatic tumor components in 5 of the 24 cases...
April 23, 2024: American Journal of Dermatopathology
https://read.qxmd.com/read/38641323/loss-of-mtap-expression-by-immunohistochemistry-is-a-surrogate-marker-for-homozygous-9p21-3-deletion-in-urothelial-carcinoma
#2
JOURNAL ARTICLE
Tatjana Vlajnic, Obinna Chijioke, Luca Roma, Spasenija Savic Prince, Tobias Zellweger, Cyrill A Rentsch, Lukas Bubendorf
Homozygous deletion of the chromosomal region 9p21.3 is common in urothelial carcinoma (UC) and leads to loss of several genes, including CDKN2A and MTAP, resulting in loss of MTAP protein expression. Here, we aimed at exploring the diagnostic potential of MTAP immunohistochemistry (IHC) as a surrogate marker for homozygous 9p21.3 deletion (9p21 HD) in UC. MTAP status was determined by IHC on 27 UC tissue specimens with known 9p21.3 status as defined by fluorescence in situ hybridization (FISH) in matched cytological specimens, by IHC and FISH on a tissue microarray (TMA) containing 359 UC at different stages, and by IHC on 729 consecutive UC from routine practice...
April 17, 2024: Modern Pathology
https://read.qxmd.com/read/38595098/discovery-of-tng908-a-selective-brain-penetrant-mta-cooperative-prmt5-inhibitor-that-is-synthetically-lethal-with-mtap-deleted-cancers
#3
JOURNAL ARTICLE
Kevin M Cottrell, Kimberly J Briggs, Douglas A Whittington, Haris Jahic, Janid A Ali, Charles B Davis, Shanzhong Gong, Deepali Gotur, Lina Gu, Patrick McCarren, Matthew R Tonini, Alice Tsai, Erik W Wilker, Hongling Yuan, Minjie Zhang, Wenhai Zhang, Alan Huang, John P Maxwell
It has been shown that PRMT5 inhibition by small molecules can selectively kill cancer cells with homozygous deletion of the MTAP gene if the inhibitors can leverage the consequence of MTAP deletion, namely, accumulation of the MTAP substrate MTA. Herein, we describe the discovery of TNG908, a potent inhibitor that binds the PRMT5·MTA complex, leading to 15-fold-selective killing of MTAP -deleted (MTAP-null) cells compared to MTAP intact (MTAP WT) cells. TNG908 shows selective antitumor activity when dosed orally in mouse xenograft models, and its physicochemical properties are amenable for crossing the blood-brain barrier (BBB), supporting clinical study for the treatment of both CNS and non-CNS tumors with MTAP loss...
April 10, 2024: Journal of Medicinal Chemistry
https://read.qxmd.com/read/38593544/genomic-insights-into-shank-and-eggshell-color-in-italian-local-chickens
#4
JOURNAL ARTICLE
Francesco Perini, Filippo Cendron, Emiliano Lasagna, Martino Cassandro, Mauro Penasa
Eggshell and shank color in poultry is an intriguing topic of research due to the roles in selection, breed recognition, and environmental adaptation. This study delves into the genomics foundations of shank and eggshell pigmentation in Italian local chickens through genome-wide association studies analysis to uncover the mechanisms governing these phenotypes. To this purpose, 483 animals from 20 local breeds (n = 466) and 2 commercial lines (n = 17) were considered and evaluated for shank and eggshell color...
March 21, 2024: Poultry Science
https://read.qxmd.com/read/38586983/guidelines-for-pathologic-diagnosis-of-mesothelioma
#5
JOURNAL ARTICLE
Aliya N Husain, David B Chapel, Richard Attanoos, Mary Beth Beasley, Luka Brcic, Kelly Butnor, Lucian R Chirieac, Andrew Churg, Sanja Dacic, Francoise Galateau-Salle, Kenzo Hiroshima, Yin P Hung, Sonja Klebe, Thomas Krausz, Andras Khoor, Leslie Litzky, Alberto Marchevsky, Kazuki Nabeshima, Andrew G Nicholson, Elizabeth N Pavlisko, Anja C Roden, Victor Roggli, Jennifer L Sauter, Jefree J Schulte, Michael Sheaff, William D Travis, Ming-Sound Tsao, Ann E Walts, Thomas V Colby
CONTEXT.—: Mesothelioma is an uncommon tumor that can be difficult to diagnose. OBJECTIVE.—: To provide updated, practical guidelines for the pathologic diagnosis of mesothelioma. DATA SOURCES.—: Pathologists involved in the International Mesothelioma Interest Group and others with expertise in mesothelioma contributed to this update. Reference material includes peer-reviewed publications and textbooks. CONCLUSIONS...
April 8, 2024: Archives of Pathology & Laboratory Medicine
https://read.qxmd.com/read/38570422/frequency-and-nature-of-genomic-alterations-in-erbb2-altered-urothelial-bladder-cancer
#6
JOURNAL ARTICLE
Jacob B Leary, Thomas Enright, Dimitra Rafailia Bakaloudi, Alina Basnet, Gennady Bratslavsky, Joseph Jacob, Philippe E Spiess, Roger Li, Andrea Necchi, Ashish M Kamat, Dean C Pavlick, Natalie Danziger, Richard S P Huang, Douglas I Lin, Liang Cheng, Jeffrey Ross, Rafee Talukder, Petros Grivas
BACKGROUND: Human epidermal growth factor-2 (HER2) overexpression is an oncogenic driver in many solid tumors, including urothelial bladder cancer (UBC). In addition, activating mutations in the ERBB2 gene have been shown to play an oncogenic role similar to ERBB2 amplification. OBJECTIVE: To describe and compare the frequency and nature of genomic alterations (GA) of ERBB2-altered (mutations, amplification) and ERBB2 wild-type UBC. PATIENTS AND METHODS: Using a hybrid capture-based comprehensive profiling assay, 9518 UBC cases were grouped by ERBB2 alteration and evaluated for all classes of genomic alterations (GA), tumor mutational burden (TMB), microsatellite instability (MSI), genome-wide loss of heterozygosity (gLOH), and genomic mutational signature...
April 3, 2024: Targeted Oncology
https://read.qxmd.com/read/38568257/mesothelioma-morphologic-and-immunohistochemical-findings
#7
REVIEW
Andrew Churg
This paper reviews some basic and some new concepts in the diagnosis of mesothelioma. The term "malignant mesothelioma" is no longer recommended; rather, any tumor labeled "mesothelioma" is presumed to be malignant. Clinical and radiologic information is very useful in the diagnosis of mesothelioma; in particular, nodular pleural thickening on CT is usually a marker of malignancy. The literature on markers that separate mesotheliomas from metastatic carcinomas has become very complex and frequently misleading, with many recommended markers actually demonstrating poor specificity...
April 3, 2024: Pathologie (Heidelb)
https://read.qxmd.com/read/38557927/loss-of-methylthioadenosine-phosphorylase-immunoreactivity-correlates-with-poor-prognosis-and-elevated-uptake-of-11-c-methionine-in-idh-mutant-astrocytoma
#8
JOURNAL ARTICLE
Toshihiro Yamamura, Kaoru Tamura, Daisuke Kobayashi, Motoki Inaji, Yuka Toyama, Hiroaki Wakimoto, Juri Kiyokawa, Shoko Hara, Yoji Tanaka, Tadashi Nariai, Kazuhide Shimizu, Kenji Ishii, Taketoshi Maehara
PURPOSE: The proximate localization of MTAP, which encodes methylthioadenosine phosphorylase, and CDKN2A/B on Chromosome 9q21 has allowed the loss of MTAP expression as a surrogate for homozygous deletion of CDKN2A/B. This study aimed to determine whether MTAP status correlates with clinical outcomes and 11 C-methionine uptake in astrocytomas with IDH mutations. METHODS: We conducted immunohistochemistry for MTAP in 30 patients with astrocytoma, IDH-mutant who underwent 11 C-methionine positron emission tomography scans prior to surgical resection...
April 1, 2024: Journal of Neuro-oncology
https://read.qxmd.com/read/38483711/advancing-brain-tumor-classification-through-mtap-model-an-innovative-approach-in-medical-diagnostics
#9
JOURNAL ARTICLE
Cuneyt Ozdemir, Yahya Dogan
The early diagnosis of brain tumors is critical in the area of healthcare, owing to the potentially life-threatening repercussions unstable growths within the brain can pose to individuals. The accurate and early diagnosis of brain tumors enables prompt medical intervention. In this context, we have established a new model called MTAP to enable a highly accurate diagnosis of brain tumors. The MTAP model addresses dataset class imbalance by utilizing the ADASYN method, employs a network pruning technique to reduce unnecessary weights and nodes in the neural network, and incorporates Avg-TopK pooling method for enhanced feature extraction...
March 14, 2024: Medical & Biological Engineering & Computing
https://read.qxmd.com/read/38468448/transcriptome-wide-gene-expression-outlier-analysis-pinpoints-therapeutic-vulnerabilities-in-colorectal-cancer
#10
JOURNAL ARTICLE
Elisa Mariella, Gaia Grasso, Martina Miotto, Kristi Buzo, Nicole Megan Reilly, Pietro Andrei, Pietro Paolo Vitiello, Giovanni Crisafulli, Sabrina Arena, Giuseppe Rospo, Giorgio Corti, Annalisa Lorenzato, Carlotta Cancelliere, Ludovic Barault, Giulia Gionfriddo, Michael Linnebacher, Mariangela Russo, Federica Di Nicolantonio, Alberto Bardelli
Multiple strategies are continuously being explored to expand the drug target repertoire in solid tumors. We devised a novel computational workflow for transcriptome-wide gene expression outlier analysis that allows the systematic identification of both overexpression and underexpression events in cancer cells. Here, it was applied to expression values obtained through RNA sequencing in 226 colorectal cancer (CRC) cell lines that were also characterized by whole-exome sequencing and microarray-based DNA methylation profiling...
March 11, 2024: Molecular Oncology
https://read.qxmd.com/read/38466661/development-of-a-series-of-pyrrolopyridone-mat2a-inhibitors
#11
JOURNAL ARTICLE
Stephen J Atkinson, Sharan K Bagal, Argyrides Argyrou, Sean Askin, Tony Cheung, Elisabetta Chiarparin, Muireann Coen, Iain T Collie, Ian L Dale, Claudia De Fusco, Keith Dillman, Laura Evans, Lyman J Feron, Alison J Foster, Michael Grondine, Vasudev Kantae, Gillian M Lamont, Scott Lamont, James T Lynch, Sten Nilsson Lill, Graeme R Robb, Jamal Saeh, Marianne Schimpl, James S Scott, James Smith, Bharath Srinivasan, Sharon Tentarelli, Mercedes Vazquez-Chantada, David Wagner, Jarrod J Walsh, David Watson, Beth Williamson
The optimization of an allosteric fragment, discovered by differential scanning fluorimetry, to an in vivo MAT2a tool inhibitor is discussed. The structure-based drug discovery approach, aided by relative binding free energy calculations, resulted in AZ'9567 ( 21 ), a potent inhibitor in vitro with excellent preclinical pharmacokinetic properties. This tool showed a selective antiproliferative effect on methylthioadenosine phosphorylase (MTAP) KO cells, both in vitro and in vivo, providing further evidence to support the utility of MAT2a inhibitors as potential anticancer therapies for MTAP-deficient tumors...
March 11, 2024: Journal of Medicinal Chemistry
https://read.qxmd.com/read/38459434/integrated-analysis-of-transcriptome-and-genome-variations-in-pediatric-t-cell-acute-lymphoblastic-leukemia-data-from-north-indian-tertiary-care-center
#12
JOURNAL ARTICLE
Minu Singh, Pankaj Sharma, Prateek Bhatia, Amita Trehan, Rozy Thakur, Sreejesh Sreedharanunni
INTRODUCTION: T-cell acute lymphoblastic leukemia (T-ALL) is a genetically heterogeneous disease with poor prognosis and inferior outcome. Although multiple studies have been perform on genomics of T-ALL, data from Indian sub-continent is scarce. METHODS: In the current study we aimed to identify the genetic variability of T-ALL in an Indian cohort of pediatric (age ≤ 12 years) T-ALL patients (n = 25) by whole transcriptome sequencing along with whole exome sequencing and correlated the findings with clinical characteristics and disease outcome...
March 8, 2024: BMC Cancer
https://read.qxmd.com/read/38423659/polyamine-inhibitor-sam486a-augments-cytarabine-cytotoxicity-in-methylthioadenosine-phosphorylase-deficient-leukemia-cells
#13
JOURNAL ARTICLE
Rie Nishi, Kei Fujita, Yasufumi Matsuda, Naoyuki Kamatani, Takahiro Yamauchi
BACKGROUND/AIM: Methionine metabolism contributes to supplying sulfur-containing amino acids, controlling the methyl group transfer reaction, and producing polyamines in cancer cells. Polyamines play important roles in various cellular functions. Methylthioadenosine phosphorylase (MTAP), the key enzyme of the methionine salvage pathway, is reported to be deficient in 15-62% of cases of hematological malignancies. MTAP-deficient cancer cells accumulate polyamines, resulting in enhanced cell proliferation...
March 2024: Anticancer Research
https://read.qxmd.com/read/38366021/eortc-specta-arcagen-study-comprehensive-genomic-profiling-and-treatment-adaptation-of-rare-thoracic-cancers
#14
JOURNAL ARTICLE
Marco Tagliamento, Marie Morfouace, Charalambos Loizides, Julio Oliveira, Laurent Greillier, Judith Raimbourg, Anne-Claire Toffart, Thierry Chatellier, Nicolas Cloarec, Ivana Sullivan, Birute Brasiuniene, Michael Duruisseaux, Kersti Oselin, Marie-Sophie Robert, Carolina Fernandes, Arnaud Poncin, Jean-Yves Blay, Benjamin Besse, Nicolas Girard
Arcagen (NCT02834884) is a European prospective study aiming at defining the molecular landscape of rare cancers for treatment guidance. We present data from the cohort of rare thoracic tumors. Patients with advanced pleural mesothelioma (PM) or thymic epithelial tumors (TET) underwent genomic profiling with large targeted assay [>300 genes, tumor mutational burden (TMB), microsatellite instability (MSI) status] on formalin-fixed paraffin-embedded (FFPE) or plasma samples. EORTC molecular tumor board (MTB) advised for biomarker-guided treatments...
February 16, 2024: NPJ Precision Oncology
https://read.qxmd.com/read/38350716/clinicopathological-characterisation-of-mtap-alterations-in-gastrointestinal-cancers
#15
JOURNAL ARTICLE
Gianluca Mauri, Giorgio Patelli, Laura Roazzi, Emanuele Valtorta, Alessio Amatu, Giovanna Marrapese, Erica Bonazzina, Federica Tosi, Katia Bencardino, Gabriele Ciarlo, Elisa Mariella, Silvia Marsoni, Alberto Bardelli, Emanuela Bonoldi, Andrea Sartore-Bianchi, Salvatore Siena
BACKGROUND: Methylthioadenosine phosphorylase (MTAP) is an essential metabolic enzyme in the purine and methionine salvage pathway. In cancer, MTAP gene copy number loss ( MTAP loss) confers a selective dependency on the related protein arginine methyltransferase 5. The impact of MTAP alterations in gastrointestinal (GI) cancers remains unknown although hypothetically druggable. Here, we aim to investigate the prevalence, clinicopathological features and prognosis of MTAP loss GI cancers...
February 13, 2024: Journal of Clinical Pathology
https://read.qxmd.com/read/38342078/discovery-of-novel-mat2a-inhibitors-by-an-allosteric-site-compatible-fragment-growing-approach
#16
JOURNAL ARTICLE
Feng Gao, Xiaoyu Ding, Zhongying Cao, Wei Zhu, Yaya Fan, Barbara Steurer, Hailong Wang, Xin Cai, Man Zhang, Alex Aliper, Feng Ren, Xiao Ding, Alex Zhavoronkov
The methionine adenosyltransferase MAT2A catalyzes the synthesis ofthe methyl donor S-adenosylmethionine (SAM) and thereby regulates critical aspects of metabolism and transcription. Aberrant MAT2A function can lead to metabolic and transcriptional reprogramming of cancer cells, and MAT2A has been shown to promote survival of MTAP-deficient tumors, a genetic alteration that occurs in ∼ 13 % of all tumors. Thus, MAT2A holds great promise as a novel anticancer target. Here, we report a novel series of MAT2A inhibitors generated by a fragment growing approach from AZ-28, a low-molecular weight MAT2A inhibitor with promising pre-clinical properties...
February 5, 2024: Bioorganic & Medicinal Chemistry
https://read.qxmd.com/read/38330461/methylthioadenosine-phosphorylase-genomic-loss-in-advanced-gastrointestinal-cancers
#17
JOURNAL ARTICLE
Natalie Y L Ngoi, Tin-Yun Tang, Catia F Gaspar, Dean C Pavlick, Gregory M Buchold, Emma L Scholefield, Vamsi Parimi, Richard S P Huang, Tyler Janovitz, Natalie Danziger, Mia A Levy, Shubham Pant, Anaemy Danner De Armas, David Kumpula, Jeffrey S Ross, Milind Javle, Jordi Rodon Ahnert
BACKGROUND: One of the most common sporadic homozygous deletions in cancers is 9p21 loss, which includes the genes methylthioadenosine phosphorylase (MTAP), CDKN2A, and CDKN2B, and has been correlated with worsened outcomes and immunotherapy resistance. MTAP-loss is a developing drug target through synthetic lethality with MAT2A and PMRT5 inhibitors. The purpose of this study is to investigate the prevalence and genomic landscape of MTAP-loss in advanced gastrointestinal (GI) tumors and investigate its role as a prognostic biomarker...
February 8, 2024: Oncologist
https://read.qxmd.com/read/38288091/molecular-prognostication-in-grade-3-meningiomas-and-p16-mtap-immunohistochemistry-for-predicting-cdkn2a-b-status
#18
JOURNAL ARTICLE
Kira Tosefsky, Karina Chornenka Martin, Alexander D Rebchuk, Justin Z Wang, Farshad Nassiri, Amy Lum, Gelareh Zadeh, Serge Makarenko, Stephen Yip
BACKGROUND: The World Health Organization 2021 classification introduces molecular grading criteria for anaplastic meningiomas, including TERT promoter ( TERTp ) mutations and CDKN2A/B homozygous deletion. Additional adverse prognostic factors include H3K27me3 and BAP1 loss. The aim of this study was to explore whether these molecular alterations stratified clinical outcomes in a single-center cohort of grade 3 meningiomas. Additionally, we examined whether p16 and MTAP immunohistochemistry can predict CDKN2A/B status...
2024: Neuro-oncology advances
https://read.qxmd.com/read/38270560/mesothelioma-of-uncertain-malignant-potential-mump-of-the-tunica-vaginalis-proposal-for-reclassification-as-complex-mesothelial-tumor-of-the-tunica-vaginalis
#19
JOURNAL ARTICLE
Chien-Kuang C Ding, Jason Van Roo, Oleksandr N Kryvenko, Huihui Ye, Jesse K McKenney, Jonathan I Epstein
A well-differentiated papillary mesothelial tumor (WDPMT) and malignant mesothelioma are 2 well-recognized entities arising from the testis tunica vaginalis. Another mesothelial lesion exclusively seen at this site is mesothelioma of uncertain malignant potential (MUMP)-a lesion reminiscent of WDPMT yet demonstrating variable proportions of more complex architectural patterns that could be confused with invasion. MUMP was first described in 2010 with a total of 11 cases reported to date. Herein, we describe 19 additional patients who underwent hydrocelectomy, excision, and/or orchiectomy...
January 25, 2024: American Journal of Surgical Pathology
https://read.qxmd.com/read/38243885/investigation-of-mtap-and-bap1-staining-loss-and-p16-cdkn2a-deletion-in-pleural-cytology-specimens-and-its-role-in-the-diagnosis-of-mesothelioma
#20
JOURNAL ARTICLE
Nazli Sena Şeker, Emel Tekin, Güntülü Ak, Muzaffer Metintaş, Selma Metintaş, Emine Dündar
BACKGROUND: Mesothelioma is a malignant neoplasm with a poor survival rate. We aimed to investigate the importance of BAP1, MTAP (IHC), and p16/CDKN2A homozygous deletion (FISH) in cytologic material obtained from pleural effusion sampling, which is a less invasive procedure in the diagnosis of mesothelioma. METHODS: Our study discussed pleural cytology samples of cases with histopathologically proven mesothelioma diagnoses between 2017 and 2022. As the control group, materials that had pleural effusion sampling for other reasons and reactive mesothelial hyperplasia were included in the study...
April 2024: Diagnostic Cytopathology
keyword
keyword
95575
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.